Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 16, 2014

View Archived Issues

Regeneron launches new human genetics initiative via new subsidiary

Portola Pharmaceuticals forms second collaboration with BMS and Pfizer

Regeneron and Bayer enter agreement to develop combination therapy for wet AMD

Crealta Pharmaceuticals completes acquisition of Savient Pharmaceuticals

BioMarin to develop factor VIII gene therapy candidate BMN-270 for hemophilia A

Synthon Biopharmaceuticals prepares for phase I study of SYD-985

Tekmira initiates dosing in phase I trial of anti-Ebola viral therapeutic

Engineered human liver tissues may be an alternate means of generating hepatitis models

NS-018 suppresses CFU-GM colony formation by BMMNCs from high-risk MDS patients

Radius Health reports topline data from phase II abaloparatide study

FDA clears IND for the CHART-2 trial in heart failure

Immunomedics begins phase III trial of yttrium Y 90 clivatuzumab tetraxetan

Synta Pharmaceuticals launches clinical trials evaluating ganetespib in cancer

Bayer reintroduces Diane-35 in France

First patient treated in Neuralstem China stem cell trial in ischemic stroke patients

AG-348 activates mutant PKLR enzymes in patient-derived red cells

AbbVie begins phase III study of veliparib in triple-negative breast cancer

Astellas Pharma reports data from phase III trials of seasonal flu vaccine

IND application filed for GR-MD-02 in metastatic melanoma

Jazz Pharmaceuticals looks towards 2014 with pipeline overview

FDA committee recommends approval of Merck & Co.'s investigational antiplatelet medicine

Italian and Belgian team patents novel anticancer compounds

AstraZeneca identifies BACE1 inhibitors

Positive allosteric modulators of mGlu2 receptors reported in BMS patent

Chinese researchers report discovery of novel DPP IV inhibitors

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...